New combo therapy shows promise for relapsed leukemia
NCT ID NCT03160079
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—blinatumomab and pembrolizumab—in 16 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) who had high levels of cancer cells in their bone marrow. The goal was to see if adding pembrolizumab to blinatumomab could improve the rate of complete remission (no detectable cancer). The study is complete, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blinatumomab and pembrolizumab
What this could lead to
If successful, this combination could improve remission rates for adults with hard-to-treat B-cell acute lymphoblastic leukemia.
What could go wrong
This is an early-phase, small trial (16 participants) with no control group, so results may not be conclusive. The drugs can cause serious side effects like infections or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC Irvine Health Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCSF Comprehensive Cancer Center
San Francisco, California, 94143, United States
-
UCSF Fresno Community Cancer Institute
Clovis, California, 93611, United States